PDCD1 and neoplasm: Antibodies that attach to the PD-1 receptor block the interaction between PD-1 and its ligands PD-L1 and PD-L2 and inhibit the signaling pathway by preventing tumor-derived PD-L1 from blocking T lymphocytes [13].